[HTML][HTML] Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
S Barbour, T Smit, X Wang, D Powers, S Arora… - Annals of …, 2017 - Elsevier
Background Rolapitant, a long-acting neurokinin (NK) 1 receptor antagonist (RA), has
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic …
B Rapoport, D Chua, A Poma, S Arora, Y Wang… - Supportive Care in …, 2015 - Springer
Purpose Rolapitant is a novel, long-acting neurokinin-1 (NK-1) receptor antagonist. This
study evaluated the safety and efficacy of four different doses of rolapitant for prevention of …
study evaluated the safety and efficacy of four different doses of rolapitant for prevention of …
Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer.
LS Schwartzberg, RM Navari, S Arora, D Powers… - 2016 - ascopubs.org
10121 Background: Addition of the neurokinin-1 receptor antagonist (RA) rolapitant to
standard antiemetic therapy improved CINV control in a phase 3 trial of patients …
standard antiemetic therapy improved CINV control in a phase 3 trial of patients …
Effects of rolapitant administered intravenously on the pharmacokinetics of a modified cooperstown cocktail (midazolam, omeprazole, warfarin, caffeine, and …
X Wang, ZY Zhang, S Arora, J Wang… - The Journal of …, 2018 - Wiley Online Library
Rolapitant is a selective, long‐acting neurokinin‐1 receptor antagonist, approved in the
United States and Europe for prevention of delayed chemotherapy‐induced nausea and …
United States and Europe for prevention of delayed chemotherapy‐induced nausea and …
Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy
PJ Hesketh, ID Schnadig, LS Schwartzberg… - Cancer, 2016 - Wiley Online Library
BACKGROUND Rolapitant, a novel neurokinin‐1 receptor antagonist, provided effective
protection against chemotherapy‐induced nausea and vomiting (CINV) in a randomized …
protection against chemotherapy‐induced nausea and vomiting (CINV) in a randomized …
Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects
ZY Zhang, J Wang, V Kansra, X Wang - Investigational New Drugs, 2019 - Springer
Rolapitant is a neurokinin-1 receptor antagonist that is approved in combination with other
antiemetic agents in adults for the prevention of delayed nausea and vomiting (CINV) …
antiemetic agents in adults for the prevention of delayed nausea and vomiting (CINV) …
Bioequivalence of intravenous and oral rolapitant: results from a randomized, open‐label pivotal study
X Wang, ZY Zhang, D Powers, J Wang… - The Journal of …, 2017 - Wiley Online Library
Rolapitant, a selective and long‐acting neurokinin‐1 receptor antagonist, is approved in an
oral formulation for the prevention of delayed chemotherapy‐induced nausea and vomiting …
oral formulation for the prevention of delayed chemotherapy‐induced nausea and vomiting …
The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy
RM Navari - Expert Opinion on Drug Safety, 2019 - Taylor & Francis
Introduction: Chemotherapy-induced nausea and vomiting is a significant clinical issue that
affects patients' quality of life as well as treatment decisions. Significant improvements in the …
affects patients' quality of life as well as treatment decisions. Significant improvements in the …
Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects
X Wang, J Wang, S Arora, L Hughes… - The Journal of …, 2019 - Wiley Online Library
Rolapitant (Varubi) is a neurokinin‐1 receptor antagonist approved for the prevention of
chemotherapy‐induced nausea and vomiting. Rolapitant is primarily metabolized by the …
chemotherapy‐induced nausea and vomiting. Rolapitant is primarily metabolized by the …
Rolapitant absolute bioavailability and PET imaging studies in healthy adult volunteers
X Wang, ZY Zhang, D Powers, J Wang… - Clinical …, 2017 - Wiley Online Library
Rolapitant, a selective, long‐acting neurokinin‐1 (NK‐1) receptor antagonist, demonstrated
efficacy in preventing chemotherapy‐induced nausea and vomiting (CINV) in patients …
efficacy in preventing chemotherapy‐induced nausea and vomiting (CINV) in patients …